Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
With the first biosimilar version of a monoclonal antibody now under regulatory review in the European Union, which R&D strategies are innovators relying on to counteract competition?
Analysis of industry pipeline data and revenue forecasts highlights several trends in the anticipated output of new drugs and the therapeutic area focus over the next 5 years, including a growth in the average number of new drug approvals annually.
The sirtuin proteins have emerged as potential regulators of mammalian lifespan, and are believed to be responsible for the health and longevity-enhancing effects of caloric restriction. Here, Baur and colleagues provide an overview of the sirtuin family, focusing on sirtuin 1 (SIRT1) and its potential to be targeted in the treatment of age-related diseases. They address the controversy surrounding the mechanism of action of resveratrol and the development of more potent SIRT1 activators.
A wealth of preclinical data on the role of neuropeptides in modulating behaviour has encouraged extensive efforts to target neuropeptide receptors for the treatment of psychiatric diseases, but so far clinical studies have not led to marketed drugs. This article analyses research on neuropeptide receptor ligands that have been studied in clinical trials, including agents that target the receptors for tachykinins, corticotropin-releasing factor and vasopressin, and suggests new ways to realize their full potential.
Metastasis is the main cause of mortality for patients with cancer. For the development of more effective treatments, a better understanding of the mechanisms of metastasis is required. In this Review, Anderson and colleagues discuss the processes underlying metastasis in breast cancer and describe how advances in the identification of relevant signalling pathways and genetic regulators can facilitate the development of novel targeted anti-metastatic drugs.
